1. Reassessing Risk Stratification in CAD/PAD

2. Program Overview

3. Aspirin for Secondary Prevention of CV Disease

4. COMPASS Trial Design

5. COMPASS Efficacy Outcomes

6. COMPASS Stroke Outcomes

7. COMPASS PAD Subgroup Amputation Outcome

8. Coagulation Cascade and Platelet Activation Pathways

9. Warfarin + Aspirin for Secondary Prevention After MI: WARIS-2

10. COMPASS Regimen Compared With Other Secondary Prevention Therapies

11. Medication Use and Lifestyle Counseling in Patients With PAD

12. Strategies for Improving Use of GDMT for Secondary Prevention

13. Trends in LE Amputation in Patients With PAD US Medicare Beneficiaries 2000-2008

14. Trends in Arterial Testing Before Amputation US Medicare Beneficiaries, 2000-2010

15. Predictors of Stroke/SE in ROCKET AF

16. Incidence of Stroke According to Prior Stroke/TIA and Baseline CrCl in ROCKET-AF

17. Identifying Patients at High Risk COMPASS Subgroup Analysis

18. Identifying Patients at High Risk COMPASS Patients Stratified by REACH Score

19. Identifying Patients at High Risk CART Analysis of COMPASS Patients

20. REACH Score Components

21. Drivers of High Risk in Patients With CAD

22. Identifying Patients at High Risk COMPASS Patients Stratified by Number of Baseline CV Risk Factors

23. COMPASS MACE Outcome by HF Status

24. COMMANDER HF

25. COMPASS CKD Subgroup

26. Underuse of Cardioprotective Medications in Patients With PAD After Diagnosis

27. COMPASS Bleeding Outcomes

28. COMPASS Landmark Analysis Frequency of GI Bleeding in Years 1, 2, and 3+

29. Association Between GI Bleeding and GI Cancer in COMPASS

30. Summary

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)